Johnson Johnson Launches Campaign to Address Depression Treatment Challenges
Johnson & Johnson has initiated the 'Generation Fine' campaign to address the challenges faced by patients with major depressive disorder (MDD) who are pessimistic about achieving symptom remission. A survey conducted by the company revealed that nearly 80% of MDD patients believe antidepressants are unlikely to address all their symptoms. The campaign, developed in collaboration with Mental Health America and clinical experts, aims to empower patients to engage in conversations with healthcare providers about their mental health. The initiative is supported by mental health advocates, including former NFL player Kyle Long, who shares his personal experiences with depression. Johnson & Johnson is also focusing on developing new therapies, such as Caplyta and Spravato, to aid patients who do not respond to conventional antidepressants. 
